Mankind Pharma Ltd (NSE: MANKIND | BSE: 543904) shares were trading around ₹2,118.60, up ₹50.40 (2.44%) on March 18, 2026. The stock opened at ₹2,066.80, touched a high of ₹2,123.10, and a low of ₹2,052.00 during the session. The company’s market capitalization is around ₹87,250 crore.
Mankind Pharma on Wednesday announced that it has acquired the well-known Rivotril brand for the Indian market from Roche. The company will have exclusive rights to manufacture, market, and distribute the product across the country.
According to the company’s official press release , Rivotril is widely prescribed for treating neurological and psychiatric conditions and is based on clonazepam. The brand has strong recognition among doctors and specialists.
The acquisition is expected to strengthen Mankind Pharma’s presence in the central nervous system (CNS) therapy segment. It will also support the company’s focus on expanding its chronic therapies portfolio, which has been growing steadily in recent years.
The company said the addition of Rivotril will complement its existing neuro portfolio and improve treatment options for patients dealing with neurological disorders.
Mankind Pharma plans to leverage its large field force and strong distribution network to expand the reach of the product across India. The company currently engages with over five lakh doctors and has a strong presence in both urban and semi-urban markets.
Commenting on the development, Atish Majumdar, Senior President (Sales & Marketing), Mankind Pharma Specialty Business, said the acquisition aligns with the company’s strategy to strengthen its position in chronic and specialty therapies, and it sees opportunities for further expansion in the CNS segment.
Mankind Pharma is one of India’s leading pharmaceutical companies with a strong presence in both pharmaceutical formulations and consumer healthcare products. The company continues to focus on providing quality medicines at affordable prices across India.
The stock reacted positively to the announcement, rising over 2% during the trading session.
